[Prophylactic HPV vaccine: "a giant leap for mankind and..." questions for our society!].
Cervical cancer remains a major public health problem in the world. The strong link between human papillomavirus (HPV) and cervical cancer brings us the opportunity to develop a prevention against HPV infection through vaccination. HPV 16 and 18 induce about 70% of all cervical cancer, so prophylactic vaccine must be focus on these types. Trails established a great safety of theses vaccines and the induction of high titer of antibodies. They provide about 100% of protection against persistent HPV 16/18 infection and associated high-grade dysplasia. HPV vaccine must be proposed to young women "HPV-naïve" before beginning of their sexual activity. But questions arise for our society: when to perform it, who would be on charge, inclusion of boys also, parental approval, adaptation of cervical screening and high cost.
Gerber
Stefan
S
Département de gynécologie et obstétrique, Maternité CHUV, 1011 Lausanne. Stefan.Gerber@chuv.ch
Gremlich
Sandrine
S
D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines
D053918:Papillomavirus Vaccines